Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

A novel chemical probe identification platform was created in which GPCR-focused libraries were screened against sets of oGPCR targets, with a goal of discovering fit-for-purpose chemical probes for ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by ...

5 One patient with SFN associated with antibodies against G Protein-Coupled Receptors (GPCR) and FGF Receptor-3 (FGFR3) after the first dose of BNT162b2 has not yet been reported. The patient is a ...

Prostaglandin E2 (PGE2), a bioactive lipid derived from arachidonic acid, mediates a broad range of physiological processes ...

Prostaglandin E2 (PGE2), a bioactive lipid derived from arachidonic acid, mediates a broad range of physiological processes through four G ...

Fintel reports that on May 14, 2025, UBS upgraded their outlook for Chimera Investment Corporation - Preferred Stock (NYSE:CIM.PRD) from Neutral to Buy. There are 11 funds or institutions ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...

kDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands lDepartment of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden University Medical ...

The combination of avutometinib and defactinib is the first FDA-approved treatment for KRAS-mutated recurrent LGSOC. Approval was based on the phase 2 RAMP-201 trial, showing a 44% overall ...

To do this, Nafizul Kazi, PhD student in the research group and first author of the study, created a chimeric protein hybrid similar to the legendary Minotaur: he incorporated related elements ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...